{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:22:59Z","timestamp":1793499779140,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejpn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejpn.2025.12.001","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:39:17Z","timestamp":1764808757000},"page":"44-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Incidence and timing of diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2): A nationwide study using the French hospital discharge database"],"prefix":"10.1016","volume":"60","author":[{"given":"St\u00e9phane","family":"Auvin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Antoine","family":"Hamandjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0631-8541","authenticated-orcid":false,"given":"Pierre","family":"Karam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9lia","family":"Hoebeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpn.2025.12.001_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejpn.2020.12.002","article-title":"Cerliponase alfa changes the natural history of children with neuronal ceroid lipofuscinosis type 2: the first French cohort","volume":"30","author":"Estublier","year":"2021","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.ejpn.2025.12.001_bib2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.pediatrneurol.2017.01.034","article-title":"Management strategies for CLN2 disease","volume":"69","author":"Williams","year":"2017","journal-title":"Pediatr. Neurol."},{"issue":"8","key":"10.1016\/j.ejpn.2025.12.001_bib3","first-page":"582","article-title":"Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study, lancet child adolesc","volume":"2","author":"Nickel","year":"2018","journal-title":"Health"},{"key":"10.1016\/j.ejpn.2025.12.001_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.785841","article-title":"Natural history studies in NCL and their expanding role in drug development: experiences from CLN2 disease and relevance for clinical trials","volume":"13","author":"Nickel","year":"2022","journal-title":"Front. Neurol."},{"issue":"20","key":"10.1016\/j.ejpn.2025.12.001_bib5","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","article-title":"Study of intraventricular cerliponase alfa for CLN2 disease","volume":"378","author":"Schulz","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ejpn.2025.12.001_bib6","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/dmcn.14346","article-title":"Paediatric-onset neuronal ceroid lipofuscinosis: first symptoms and presentation at diagnosis","volume":"62","author":"Dozi\u00e8res-Puyravel","year":"2020","journal-title":"Dev. Med. Child Neurol."},{"issue":"8","key":"10.1016\/j.ejpn.2025.12.001_bib7","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/jpc.14890","article-title":"Neuronal ceroid lipofuscinosis type 2: an Australian case series","volume":"56","author":"Johnson","year":"2020","journal-title":"J. Paediatr. Child Health"},{"issue":"4","key":"10.1016\/j.ejpn.2025.12.001_bib8","first-page":"272","article-title":"The neuronal ceroid lipofuscinosis type 2 - associated variants: an analysis of alterations in the TPP1 gene and genotype-phenotype correlation in Ukraine","volume":"65","author":"Olkhovych","year":"2024","journal-title":"JIMD Rep"},{"issue":"3","key":"10.1016\/j.ejpn.2025.12.001_bib9","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1055\/s-0043-1761434","article-title":"Clinical management and diagnosis of CLN2 disease: consensus of the Brazilian experts group","volume":"81","author":"Sampaio","year":"2023","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.ejpn.2025.12.001_bib10","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/B978-0-444-59565-2.00038-1","article-title":"Neuronal ceroid lipofuscinoses","volume":"113","author":"Chabrol","year":"2013","journal-title":"Handb. Clin. Neurol."},{"issue":"5","key":"10.1016\/j.ejpn.2025.12.001_bib11","first-page":"1","article-title":"A needle in a haystack? The impact of a targeted epilepsy gene panel in the identification of a treatable but rapidly progressive metabolic epilepsy: CLN2 disease","volume":"82","author":"Louren\u00e7o","year":"2024","journal-title":"Arq. Neuropsiquiatr."},{"issue":"6","key":"10.1016\/j.ejpn.2025.12.001_bib12","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1055\/s-0043-1770143","article-title":"Language delay in patients with CLN2 disease: could it support earlier diagnosis?","volume":"54","author":"Nickel","year":"2023","journal-title":"Neuropediatrics"},{"issue":"4","key":"10.1016\/j.ejpn.2025.12.001_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214649","article-title":"Identifying chronic thromboembolic pulmonary hypertension through the French national hospital discharge database","volume":"14","author":"Cottin","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpn.2025.12.001_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1245228","article-title":"Botulinum toxin use in patients with post-stroke spasticity: a nationwide retrospective study from France","volume":"14","author":"Levy","year":"2023","journal-title":"Front. Neurol."},{"issue":"4","key":"10.1016\/j.ejpn.2025.12.001_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0298234","article-title":"Epidemiology of congenital heart defects in France from 2013 to 2022 using the PMSI-MCO (French Medical Information System program in medicine, surgery, and obstetrics) database","volume":"19","author":"Bourdon","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpn.2025.12.001_bib17","article-title":"Scurvy incidence trend among children hospitalised in France, 2015-2023: a population-based interrupted time-series analysis","volume":"49","author":"Assad","year":"2024","journal-title":"Lancet Reg. Health Eur."},{"issue":"3","key":"10.1016\/j.ejpn.2025.12.001_bib18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10048-005-0218-3","article-title":"Correlations between genotype, ultrastructural morphology and clinical phenotype in the neuronal ceroid lipofuscinoses","volume":"6","author":"Mole","year":"2005","journal-title":"Neurogenetics"},{"issue":"2","key":"10.1016\/j.ejpn.2025.12.001_bib19","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.gene.2016.08.031","article-title":"Analysis of large-scale whole exome sequencing data to determine the prevalence of genetically-distinct forms of neuronal ceroid lipofuscinosis","volume":"593","author":"Sleat","year":"2016","journal-title":"Gene"},{"issue":"1","key":"10.1016\/j.ejpn.2025.12.001_bib20","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s13023-021-01858-6","article-title":"Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa","volume":"16","author":"Schaefers","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"issue":"1\u20132","key":"10.1016\/j.ejpn.2025.12.001_bib21","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ymgme.2016.07.011","article-title":"Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): expert recommendations for early detection and laboratory diagnosis","volume":"119","author":"Fietz","year":"2016","journal-title":"Mol. Genet. Metabol."},{"issue":"1","key":"10.1016\/j.ejpn.2025.12.001_bib22","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s13023-021-01813-5","article-title":"Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients","volume":"16","author":"Mole","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.ejpn.2025.12.001_bib23","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1474-4422(23)00384-8","article-title":"Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension study","volume":"23","author":"Schulz","year":"2024","journal-title":"Lancet Neurol."}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379825001801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379825001801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T19:29:36Z","timestamp":1774294176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090379825001801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":22,"alternative-id":["S1090379825001801"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2025.12.001","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence and timing of diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2): A nationwide study using the French hospital discharge database","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2025.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Paediatric Neurology Society.","name":"copyright","label":"Copyright"}]}}